Table 1.
Case descriptions for the six HGSC patients profiled in this study
| Case no. | Age | Stage | Treatment | BRCA status | Progression-free survival (months) | Overall survival (months) | Patient status | Number of samples | Index samples (exome) | Index samples (Affy SNP 6.0) | Index samples (Affy U133 expression) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spatial | 1 | 56 | IV | IV CP×6 | Unknown (declined) | 24 | 29 | Alive, recurrent disease, 3rd line chemo | 4 (right ovary, quadrants 1a–d) | 4 (All and normal) | 4 (All and normal) | 4 (right ovary, quadrants 1a–d) |
| 2 | 59 | IIIA | IV/IP CP×3, IV×3 | Screen negative | 27 | 27 | Alive, no evidence of disease | 4 (right ovary, quadrants 2a–d) | 4 (All and normal) | 4 (All and normal) | 4 (right ovary, quadrants 2a–d) | |
| 3 | 64 | IIIC | IV/IP CP×6 | Unknown (moved) | 9 | 9 | Unknown (moved) | 3 (3a, right ovary; 3b, left ovary; 3c, posterior cul de sac) | 3 (All and normal) | 3 (All and normal) | 3 (3a, right ovary; 3b, left ovary; 3c, posterior cul de sac) | |
| 4* | 79 | IIIC | IV CP×6 | Screen negative | 15 | 17 | Alive, recurrent disease, 2nd line chemo | 10 (4a–e, right ovary; 4f–i, left ovary; 4j, left fallopian tube) | 1 (4a and normal) | 9 (4a–i, and normal) | 9 (4a–e, right ovary; 4f–i, left ovary) | |
| 5* | 73 | IIIC | IV CP×6 | Unknown (declined) | 17 | 17 | Alive, no evidence of disease | 8 (5a, right ovary; 5b–e, left ovary; 5f, left iliac node; 5g, left para-aortic node; 5h, left fallopian tube) | 5 (5a–c, f, g and normal) | 5 (5a–c, f, g and normal) | 7 (5a, right ovary; 5b–e, left ovary; 5f, left iliac node; 5g, left para-aortic node) | |
| Temporal | 6 | 65 | IIIC | Primary Rx: IV CP×6 Recurrence Rx; 21 cycles (multiple agents) | Screen negative | 13 | 74 | Dead of disease | 2 (6a, omentum (primary surgery); 6b, left ovary (recurrence)) | 2 (both and normal) | 2 (both and normal) | 2 (6a, omentum (primary surgery); 6b, left ovary (recurrence)) |